Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claims 1-3 and 7-15 are rejected under 35 U.S.C. 101 because the claimed invention is directed to judicial exceptions encompassing abstract ideas and a natural phenomenon without significantly more.
The claims include steps (as recited in claim 1) of: “determining … one or more bases in the first sequence read to be soft-clipped”; “soft clipping, by the one or more processors, bases”; and determining … a length or sequence of the 5' overhang of the second strand of the cell-free DNA duplex based on the soft clipping”. These aspects of the claims are abstract idea such as the evaluation of data or information to reach a conclusion (see MPEP 2106.04(a) III). These steps are the evaluation of sequencing data to determine sequence processing steps, where the processing steps are themselves data processing that is encompassed by the abstract idea (mental processes) judicial exception (e.g.: soft clipping is an alignment process where portions of a sequencing read do not match the reference genome, but the unaligned bases are retained in the alignment results rather than being deleted). The evaluation of processes data to make a conclusion about an overhang length or sequence is similarly considered to be an abstract idea. Here it is noted that while the clams include steps performed “by one or more processors”, the recitation of a general use a computer program is not itself sufficient to overcome a rejection made under 35 USC 101 (see MPEP 2106.05(b) and MPEP 2106.04(a)(2)(III)). The claims additionally recite aspects of associating a determined overhang length or sequence to the presence or absence of a disease (e.g.: claims 2, 3, 13). Such an association is an abstract idea (i.e.: the mental correlation of data and information to reach a conclusion), and where such an association is a natural part of organism biology (i.e.: the presence of some particular fragment overhangs in the presence of some pathology) the claims are directed to a natural phenomenon (see MPEP 2106.04(b) I).
This judicial exception is not integrated into a practical application because there are no required practical steps related to any particular determined a length or sequence of the overhangs. The claimed methods end with making a determination, which are abstract ideas as detailed above.
The claim(s) does/do not include additional elements that are sufficient to amount to significantly more than the judicial exception because the data gathering steps of the claims (i.e.: extending a 3’-end of a duplex with inosine to fill in a 5’ overhang, attaching an adapter, and sequencing the duplex) is activity that was well understood, routine, and conventional in the related art, as evidenced by the teachings of the prior art of WO-2020020174 and US PG Pub 20180051329 (citations provided on the IDS of 04/28/2025)
Thus the claims are properly rejected as being directed to a judicial exception to patentability without significantly more.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 2, 3, 5, 13, 19 and 20 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
The rejected claims are directed to methods of determining a length or sequence of an overhang of cell-free DNA duplex, and then detecting a presence or absence of a disease based on the length or sequence of the overhang. The claims thus require knowledge of an association between the length or sequence of the overhang and the presence or absence of a disease. Practicing the claimed methods thus requires the skilled artisan to be in possession of information which correlates overhand length or sequence with the presence of a pathology.
The claims are generically broad with regard to the detected analytes (i.e.: the claims encompass the determination of overhangs of any length and any sequence content). The claims are further generically broad with the associated phenotype (i.e.: the claims encompass the detection of any pathological state). But neither the teachings of the application as filed, nor the related art, provide the skilled artisan with a basis of knowledge or information to be able to establish that any disease is present or absent based on the detection of any overhang length or sequence. In this regard the specification teaches only that a determined overhang “can be analyzed to disease associations, such as cancer” (e.g.: para 0113). The specification asserts (e.g.: para 0151) that overhangs can be analyzed in case and control populations. But the mere teaching that some analysis may be performed is not a disclosure or description of the results required to make the detection of the rejected claims. The idea that an association may be investigated does not provide the skilled artisan to choose from the vastly encompassed genus of overhang lengths and sequences, and pathological states, those elements which may be associated. This finding is also emphasized in Ex Parte Kubin (No. 2007-0819, Bd. Pat. App. & Int. May 31, 2007), wherein it is stated that:
“Although there is often significant overlap” between the enablement and written description requirements, “they are nonetheless independent of each other.” University of Rochester, 358 F.3d at 921, 69 USPQ2d at 1891. An “invention may be enabled even though it has not been described.” Id. Such is the situation here. While we conclude one skilled in the art would have been able to make and use the full scope of claim 73 through routine experimentation, we find Appellants did not describe the invention of claim 73 sufficiently to show they had possession of the claimed genus of nucleic acids. See, e.g., Noelle v. Lederman, 355 F.3d 1343, 1348, 69 USPQ2d 1508, 1513 (Fed. Cir. 2004) (“invention is, for purposes of the ‘written description’ inquiry, whatever is now claimed”).
Thereby, a showing of how to potentially identify cell-free duplex overhanges that might be used in the claimed methods is not sufficient to establish that Applicants were in possession of the invention as broadly claimed.
Conclusion
Claims 16-18 are allowed.
Claims 4 and 6 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Claim 4, from which claim 6 depends) and claim 16 (from which claims 17 and 18 depend), are directed to methods including determining the sequence of a 3’ overhang in a second strand of a DNA duplex in which an adapter is attached to a 3’ overhang in a second strand of a duplex, a 3’ end of the adapter is extended with inosine bases to fill in the 3’ overhang of the duplex, and the 3’ inosine-extended end of the adapter is attached to the 5’ end of the first strand of duplex. The prior art does not teach an adapter used in the steps of attaching to a 3’ end of a second strand, filling in with inosine, and attaching to the 5’ end of a first strand; these methods are free of the prior art, and including methodological steps (as described above) which are not well understood, routine and conventional in view of the related art (and thus are more than the judicial exceptions that are included in the claims). The closest prior art related to filling in a 3’ overhang via post-attachment extension of an adapter is Zhu et al (2016) (e.g.: Fig 4A), Akopiants et al (2009) (e.g.: Fig 1A), and Zwirko et al (US PG Pub 20190010540) (e.g.: Fig 1). However, none of the prior art suggests extension of the attached adapter with inosine, as taught by the instant application, to make the 3’ overhang detectable via a sequencing procedure.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to STEPHEN THOMAS KAPUSHOC whose telephone number is (571)272-3312. The examiner can normally be reached M-F, 8am-5pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anne Gussow can be reached at 571-272-6047. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
Stephen Kapushoc
Primary Examiner
Art Unit 1683
/STEPHEN T KAPUSHOC/Primary Examiner, Art Unit 1683